Back to Portfolio
MOH

Molina Healthcare

$149.2 7.7B market cap March 15, 2026
🎧 Audio Deep Dive
Listen to the full educational narration of this analysis
0:00 --:--
Molina Healthcare Inc MOH BUFFETT / MUNGER / KLARMAN SUMMARY
1 SNAPSHOT
Price$149.2
Market Cap7.7B
2 BUSINESS

Molina Healthcare is a pure-play Medicaid managed care operator experiencing a cyclical margin trough driven by Medicaid rate underfunding estimated at 300-400 bps nationally. The 58% stock decline from $360 to $149 prices in permanent impairment, but the evidence suggests this is a temporary rate lag that will normalize over 12-24 months as states incorporate higher medical costs into actuarial rate-setting. At 1.87x book and ~8x normalized earnings, with both Klarman (2.05% of Baupost) and Burry (~35% of Scion) converging on the same thesis, the risk/reward is attractive for patient investors willing to tolerate a 2026 trough year with $5.00 adjusted EPS before recovery to $18-22 normalized EPS in 2027-2028. Key risks are federal Medicaid policy changes and the timing of rate corrections; key catalysts are rate increases, Florida/Georgia contract ramps, and MAPD exit.

3 MOAT NARROW

State Medicaid contract incumbency, 6.5% G&A ratio (industry-best), 44 years Medicaid expertise, RFP complexity creates barriers to entry

4 MANAGEMENT
CEO: Joseph Zubretsky

Good operator but questionable 2025 capital allocation -- $1B buybacks funded by debt during negative FCF year. Strong long-term track record: revenue 2.4x, stock 6x from 2017 lows.

5 ECONOMICS
1.7% Op Margin
8.5% ROIC
11.6% ROE
16.73x P/E
-0.64B FCF
-7% Debt/EBITDA
6 VALUATION
FCF Yield11%
DCF Range210 - 260

Undervalued by 29-43% vs probability-weighted fair value of $210-$260

7 MUNGER INVERSION
Kill Event Severity P() E[Loss]
Medicaid rate underfunding -- 300-400 bps below sustainable levels nationally, timing of rate correction uncertain HIGH - -
Federal Medicaid policy risk -- block grants or per-capita caps could structurally impair the business model MED - -
8 KLARMAN LENS
Downside Case

Medicaid rate underfunding -- 300-400 bps below sustainable levels nationally, timing of rate correction uncertain

Why Market Right

Federal Medicaid funding cuts or block grant conversion; Delayed rate recovery if states face budget constraints; Q1 2026 earnings miss could push stock to new lows; ACA enhanced subsidy expiration reducing Marketplace membership; Another year of negative FCF would strain balance sheet

Catalysts

Medicaid rate increases as states catch up to higher medical costs (2H 2026 - 2027); Florida $5B SMMC contract ramp -- accretive once $1.50/share implementation drag passes; Georgia $2B Medicaid contract -- new market entry adding scale; Medicare MAPD exit in 2027 -- removes money-losing segment, improves MCR; Share buybacks at trough prices -- $1B+ at $120-$150 vs $300+ historically; M&A target potential -- pure-play Medicaid MCO attractive to larger acquirers

9 VERDICT WAIT
B+ Quality Moderate -- $4.25B cash offsets $3.95B debt, but negative FCF in 2025 and rising leverage (D/E from 0.69 to 0.97) are concerns. No dividend paid.
Strong Buy$110
Buy$135
Fair Value$260

Accumulate at $125-135 (10% below current), Strong Buy below $110. Current $149 offers reasonable value but recent $121 low shows further downside possible if Q1 2026 disappoints.

🧠 ULTRATHINK Deep Philosophical Analysis

MOH - Ultrathink Analysis

A Buffett/Munger meditation on Molina Healthcare

The Real Question: Is This GEICO, or Is This an Airplane Manufacturer?

Michael Burry compared Molina to "early GEICO" -- an insurer with superior cost structure trading at trough prices because the market conflates cyclical margin compression with structural decline. The comparison is instructive, but it demands honest scrutiny.

What made GEICO special was not just low costs -- it was that GEICO's cost advantage was structural and permanent. Direct-to-consumer auto insurance eliminated the agent commission, permanently reducing costs by 10-15 percentage points. No competitive response could replicate this advantage without destroying the agent distribution channel that competitors depended on.

Molina's 6.5% G&A ratio is genuinely excellent, and it stems from real operational discipline cultivated over 44 years of Medicaid focus. But is this advantage as permanent as GEICO's? The honest answer is: probably not. A larger MCO with enough willpower could achieve similar G&A through scale alone. UnitedHealth, Centene, and Elevance all have comparable or greater scale. Molina's edge is narrower -- it comes from focus rather than structure. Focus can drift. Structure endures.

Still, the GEICO analogy holds in one critical dimension: when the insurance cycle turns against you, the low-cost operator survives while marginal competitors bleed. Burry's core insight -- that Molina will make money in Medicaid in 2026 while competitors lose money -- is the kind of asymmetric observation that creates generational entry points.

Hidden Assumptions: The Government as Customer

Charlie Munger would immediately identify the central paradox of Molina's business: the company's greatest strength (guaranteed government revenue) is also its greatest vulnerability (zero pricing power).

In a normal business, a company with Molina's operational efficiency would translate that advantage into higher prices, wider margins, and compounding returns. But Molina cannot set its own prices. It takes whatever PMPM rate the state actuary determines, and its only lever is managing costs below that rate. This fundamentally caps the upside while leaving the downside unbounded -- if medical costs surge and rates lag, margins compress regardless of operational excellence.

This is not a moat in the Buffett sense of a durable competitive advantage that enables pricing power. It is more accurately described as an operational advantage within a regulated commodity-like business. The incumbency advantage in Medicaid contracts is real -- states prefer continuity, RFP processes favor established operators, and network adequacy requirements create genuine barriers. But this is a narrow moat, not a wide one.

Munger's concept of "incentive-caused bias" applies here too. State Medicaid agencies have an inherent incentive to set rates as low as possible (they are spending taxpayer money), while MCOs have an inherent incentive to argue rates are inadequate (it increases their margins). The truth lies between these positions, and the current 300-400 bps underfunding claim, while likely directionally correct, should be taken with appropriate skepticism about its magnitude.

The Soul of the Business: Would Buffett Hold This for 20 Years?

Emphatically, no. This is not a Buffett-style holding, and pretending otherwise would be intellectually dishonest.

Buffett wants businesses where he can predict with reasonable confidence what the company will look like in 10-20 years. Molina's business is subject to government policy changes that could fundamentally alter its economics overnight. A serious push toward Medicare-for-All, Medicaid block grants, or even aggressive managed care regulation could dramatically change the landscape. The business exists at the pleasure of government -- it is an intermediary that government tolerates because private sector MCOs have historically managed Medicaid more efficiently than government directly, but this arrangement is not guaranteed.

However, Molina is absolutely a Klarman-style investment. Klarman specializes in buying quality assets at distressed prices when temporary headwinds create forced selling and fear. He does not need 20-year durability -- he needs 2-3 years of margin recovery plus the margin of safety to be protected if he is wrong. At 1.87x book and 8x normalized earnings, with $4.25B in cash on the balance sheet, the downside is substantially cushioned even in an adverse scenario.

This is the crucial distinction. Molina is not a "forever stock." It is a cyclical-recovery trade in a business with genuine, if narrow, competitive advantages. The position sizing should reflect this -- a 2-4% allocation, not a 10-15% conviction position.

The Contrarian View: What Could Destroy This Business?

Inverting, as Munger instructs, we ask: what would have to be true for Molina to be worth significantly less than $149?

Path to $50-75 (67-50% downside):

  1. Federal government converts Medicaid to block grants, cutting per-capita spending 15-20%
  2. States respond by either reducing MCO payments or bringing Medicaid administration in-house
  3. Molina's $45B revenue base shrinks by 20-30% while fixed costs remain
  4. Margins collapse permanently, FCF stays negative, debt becomes unserviceable
  5. Company is eventually acquired at distressed prices or restructures

Path to $200-300 (34-100% upside):

  1. Medicaid rates catch up to medical costs over 12-24 months (actuarially inevitable absent policy changes)
  2. Operating margins normalize to 3.5-4.5% (historical norm)
  3. Florida and Georgia contracts ramp to full profitability
  4. EPS recovers to $18-22 range
  5. Market re-rates from trough multiple (8x) to mid-cycle multiple (14-16x)

The asymmetry is favorable -- the bear case requires policy changes that are politically difficult (cutting healthcare for 80M+ Americans), while the bull case requires only reversion to historical norms in an actuarially-driven rate-setting process. The base rate for rate normalization is very high; the base rate for radical Medicaid restructuring is lower, though not negligible in the current political environment.

The Simplest Thesis: Trough Earnings vs. Normalized Earnings

The fundamental valuation question is deceptively simple: what are you paying for, and what are you getting?

What the market sees: A company earning $5.00 adjusted EPS in 2026, trading at 30x those trough earnings. That looks expensive.

What value investors see: A company with $18-22 normalized EPS (2022-2024 average), growing revenue at 10%+ annually, with a 23% average ROE over the prior four years, temporarily depressed by a cyclical rate lag. At 8x normalized earnings, it is among the cheapest managed care stocks in a decade.

The Graham framework is instructive here. Graham taught that the investor's chief problem -- and his worst enemy -- is himself. The Q4 2025 earnings miss, the negative cash flow, the shareholder lawsuits, the analyst downgrades -- these create the emotional conditions that force selling and create value. Mr. Market is offering this business at a deeply discounted price precisely because the near-term news is terrible.

But Graham also taught that margin of safety is paramount. At $149, the margin of safety to normalized fair value ($210-$260) is 29-43%. That is adequate but not extraordinary. At $110-$135, the margin of safety expands to 36-58%, which is genuinely compelling. The investor's task is patience -- waiting for the pitch, not swinging at everything.

The Patient Investor's Path

The convergence of Klarman and Burry on this stock is a powerful signal, but it should not substitute for independent judgment. Both are sophisticated investors who have been wrong before (Burry's timing on the Big Short was agonizing; Klarman has sat on underperforming positions for years).

The right approach is staged:

Stage 1 (Now, $149): Research position established. Understand the business, the rate cycle, the risks. Monitor Q1 2026 earnings (likely April 2026) for early signs of rate improvement.

Stage 2 ($125-135): Begin accumulating. At these prices, normalized P/E drops to 7-7.5x, providing 36-48% margin of safety. Size at 1-2% of portfolio.

Stage 3 ($110 or below): Aggressive accumulation. At 6x normalized earnings, the market is pricing in structural impairment. If the business model is intact (which rate recovery would prove), this is a strong buy. Size up to 3-4%.

Stage 4 (Margin recovery confirmed, $180+): Hold for re-rating. As quarterly MCR data improves and guidance lifts, the market will re-rate. Target exit at $250-$300 (14-16x normalized EPS).

The expected holding period is 2-3 years. This is not a quick trade -- it is a patient thesis on reversion to the mean in an actuarially-driven business, supported by the conviction of two of history's most successful value investors, at prices that provide genuine margin of safety even if the recovery takes longer than expected.

The question is not whether Medicaid rates will normalize -- they mathematically must, because states cannot indefinitely pay MCOs below cost without losing plan participation. The question is when, and whether the balance sheet can bridge the gap. At $149 with $4.25B in cash, the answer is almost certainly yes. The patient investor wins.

"The stock market is a device for transferring money from the impatient to the patient." -- Warren Buffett

Executive Summary

Molina Healthcare is a pure-play government-sponsored managed care company, operating Medicaid, Medicare, and ACA Marketplace health plans across 20 states. The stock has collapsed 58% from its 52-week high of $359.97 to $149.20 following a disastrous Q4 2025 that saw a GAAP loss of $3.15/share and sharply reduced 2026 guidance. Both Seth Klarman (Baupost, 2.05% of portfolio at ~$173/share) and Michael Burry (Scion, ~35% of portfolio) have taken positions, viewing the selloff as a cyclical trough in Medicaid rates rather than structural impairment.

The investment thesis hinges on whether Molina's Medicaid margin compression is temporary (cyclical rate underfunding that reverses in 2027-2028) or permanent (structural inability to manage medical costs). The evidence strongly favors the former interpretation, though the 2026 trough will test the balance sheet and management's credibility.

Verdict: WAIT -- accumulate at $125-135, strong buy below $110.

1. Business Model

What Molina Does

Molina Healthcare administers government-sponsored health insurance programs. It does not provide medical care directly; it manages networks of providers, processes claims, and assumes the insurance risk on per-member-per-month premiums paid by state and federal governments.

Revenue Breakdown (FY 2025 Premium Revenue: $43.1B):

Segment Premium Revenue Members % of Total
Medicaid ~$34.4B 4.57M ~80%
Medicare ~$3.4B 262K ~8%
Marketplace (ACA) ~$5.3B 655K ~12%

How the Business Works

  1. State/Federal Government pays Molina a fixed per-member-per-month (PMPM) premium, set via actuarial rate-setting processes
  2. Molina pays providers (hospitals, doctors, pharmacies) for members' healthcare via its managed care network
  3. The spread between premiums received and medical costs paid is the Medical Care Ratio (MCR) -- Molina's critical operating metric
  4. Molina's profit comes from keeping MCR below 88-89%, maintaining G&A ratio around 6.5%, and earning investment income on float

The business model is essentially insurance underwriting on government-set prices, where the company's competitive edge comes from:

  • Cost management: Keeping medical costs below actuarially-set premiums
  • Scale efficiencies: Spreading fixed G&A costs across a larger membership base
  • Rate negotiation: Having actuarial expertise to advocate for adequate rates

The Medicaid Rate Cycle Dynamic

This is the single most important concept for understanding Molina's current situation:

  1. Medicaid rates are set by states, typically annually, based on prior-year medical cost data
  2. When utilization surges (as in 2024-2025 post-redetermination), rates lag behind actual costs
  3. Rates eventually catch up as states incorporate higher-cost data into new actuarial rates
  4. Lag period is typically 12-24 months, creating cyclical margin compression followed by recovery

Management estimates Medicaid is underfunded by 300-400 basis points nationwide. This means the entire industry is operating below sustainable margins, and rate corrections are actuarially necessary.

2. Geographic Footprint

Molina operates Medicaid plans in approximately 20 states:

Major Markets (by premium revenue):

  • California, Florida, Washington, Michigan, Ohio, Texas, New York
  • Washington State alone represents 13% of Medicaid premium revenue ($4.2B)
  • Awarded new Florida SMMC contract (sole plan, ~$5B premium, implementation starting 2026)
  • Awarded new Georgia Medicaid contract (~$2B annual premium)

Key Strategic Developments:

  • Florida CMS sole-source contract: Major win, but $1.50/share implementation drag on 2026 earnings
  • Georgia expansion: ~$2B incremental annual premium beginning ramp
  • Medicare exit: Exiting traditional MAPD business in 2027 ($1.00/share drag in 2026)
  • ConnectiCare acquisition: Closed Q1 2025, expanding ACA Marketplace presence

3. Competitive Position & Moat Assessment

Moat Type: Regulatory + Scale (Narrow to Moderate)

Moat Sources:

  1. Regulatory Barriers (Primary)

    • State Medicaid contracts require extensive licensure, actuarial capability, and provider network adequacy
    • RFP processes are long and complex; incumbency advantage is significant
    • State regulators prefer continuity -- disruption harms vulnerable populations
    • Multi-year contracts create revenue visibility (though rate resets add risk)

  2. Scale Efficiencies

    • G&A ratio of 6.5% is among the best in managed care
    • Spreading IT systems, compliance infrastructure, and actuarial teams across 5.5M members
    • Larger membership = better claims data = better risk management

  3. Operational Expertise

    • 44 years of Medicaid-focused operations since founding in 1980
    • Deep institutional knowledge of Medicaid populations (complex, high-acuity)
    • Track record of successfully onboarding new state contracts

Moat Weaknesses:

  • No pricing power: Rates are set by governments, not by Molina
  • Single payer risk: Government can change rules unilaterally
  • Low switching costs: Members are assigned, not choosing Molina voluntarily
  • Contract renewal risk: Contracts must be rebid periodically

Moat Width: NARROW -- Incumbent advantage is real but dependent on government policy. Not a wide moat like a Visa or Costco.

Competitive Landscape

Company Medicaid Members Focus
UnitedHealth (UNH) ~8M Diversified (Optum growth engine)
Centene (CNC) ~16M Largest Medicaid MCO, diversified
Elevance/Anthem (ELV) ~10M Blue Cross franchise, diversified
Molina (MOH) 4.6M Pure-play government, lowest G&A
CVS/Aetna ~3M Integrated pharmacy + care

Molina is smaller than peers but often cited as the most operationally efficient pure-play Medicaid MCO.

4. Financial Analysis

Income Statement Trends (5 Years)

Year Revenue Op Margin Net Margin EPS (Adj) ROE
2025 $45.4B 1.7% 1.0% $11.03 11.6%
2024 $40.7B 4.2% 2.9% $22.65 26.7%
2023 $34.1B 4.6% 3.2% $18.77 26.2%
2022 $32.0B 3.7% 2.5% $13.94 26.8%
2021 $27.8B 3.7% 2.4% $11.55 25.5%

Revenue CAGR (5yr): 10.3% -- Consistent double-digit growth driven by membership gains + rate increases + acquisitions.

Key Observation: 2025 was an aberration. Operating margins collapsed from a consistent 3.7-4.6% range to 1.7%, entirely driven by elevated MCR. The question is whether this is a one-off cyclical trough or a new normal.

Medical Care Ratios (The Critical Metric)

Period Medicaid Medicare Marketplace Consolidated
FY 2025 91.8% 92.4% 90.6% 91.7%
Q4 2025 93.5% 97.5% 99.0% 94.6%
FY 2024 ~90.0% ~88.3% ~74.0% ~89.5%
Target Range 88-89% 87-88% 73-75% ~88-89%

Q4 2025 was catastrophic across all segments. Key drivers:

  • Medicaid: Unfavorable retroactive premium rate actions in California (~$2.00/share impact)
  • Medicare: Elevated LTSS utilization + high-cost drugs (97.5% MCR = losing money)
  • Marketplace: Elevated utilization + prior-period provider claim settlements (99% MCR = breakeven)

Balance Sheet

Metric FY 2025 FY 2024
Total Assets $15.6B $15.6B
Stockholders' Equity $4.07B $4.50B
Cash & Investments $4.25B $4.66B
Total Debt $3.95B $3.12B
Net Debt ~$(0.3)B ~$(1.5)B
Debt/Equity 0.97 0.69
Book Value/Share $79.78 ~$85
Days Claims Payable 47 days N/A

Concern: Debt increased ~$830M in 2025, likely to fund operations during negative cash flow period and the ConnectiCare acquisition. Leverage has risen but remains manageable for an insurance company.

Cash Flow

Year Operating CF CapEx FCF Buybacks
2025 -$535M $101M -$636M $1,037M
2024 $644M $100M $544M $1,057M
2023 $1,662M $84M $1,578M $60M
2022 $773M $91M $682M $454M
2021 $2,119M $77M $2,042M $181M
5yr Average $933M $91M $842M $558M

FCF went negative in 2025 -- This is the scariest data point. Operating cash flow turned deeply negative while the company still spent $1B+ on buybacks. This was funded by debt. If 2026 cash flow doesn't recover, the buyback program must be curtailed.

However, context matters: Managed care cash flows are lumpy due to claims timing, medical loss reserve development, and premium payment timing. A single year of negative FCF after four years of strong positive FCF is not necessarily alarming.

5. Management Assessment

CEO: Joseph Zubretsky (since November 2017, 8+ years)

Track Record:

  • Inherited a struggling company with sub-par margins and governance issues (prior CEO Mario Molina was fired)
  • Revenue grew from ~$19B (2017) to $45.4B (2025) -- 2.4x growth
  • Stock price rose from ~$70 (2017) to peak of $424 (2024) -- 6x return before the selloff
  • Built aggressive acquisition pipeline (Magellan, ConnectiCare, Bright Health CA)
  • Maintained industry-best G&A ratio (~6.5%)

Compensation & Alignment:

  • Total comp ~$22M (7.3% salary, 92.7% stock-based)
  • Owns 298,910 shares (~$44.5M at current prices, 0.58% of company)
  • Red flag: All transactions in last 5 years have been sales, no purchases
  • Contract extended through 2027

Capital Allocation:

  • Aggressive share buybacks: $2.6B over 2022-2025 (reduced share count from ~58M to ~51M)
  • Continued buybacks even during negative FCF year (2025) -- questionable capital allocation
  • Acquisition-driven growth strategy with mixed results (ConnectiCare TBD, Bright Health MAPD underperforming)

Assessment: Good operator, questionable capital allocator in 2025. Buying back $1B of stock while operating cash flow was negative and funded by debt is not Buffett-quality capital allocation. However, his operational track record transforming Molina is undeniable.

6. Risk Analysis

Primary Risk: Medicaid Rate Underfunding (HIGH)

Management estimates Medicaid is underfunded by 300-400 bps nationally. While rates should eventually correct (actuarial necessity), the timing is uncertain. If states delay rate increases due to budget constraints, margins could remain compressed through 2027.

Secondary Risk: Government Policy (MODERATE-HIGH)

  • Medicaid funding cuts: Federal proposals to convert Medicaid to block grants or per-capita caps could fundamentally alter the business model
  • Enhanced subsidy expiration: ACA Marketplace enhanced subsidies may expire, potentially reducing Marketplace membership
  • CMS regulatory changes: Changes to managed care rules, MLR floors, or payment methodologies

Cyclicality: MODERATE

Medicaid managed care is counter-cyclical (membership grows in recessions) but margins are cyclical due to rate lag. Revenue is highly recession-resistant; profits are not.

Concentration Risk

  • Washington State = 13% of Medicaid premium revenue (single contract risk)
  • California retroactive rate action in Q4 2025 demonstrates state-level concentration risk
  • Florida new contract = $5B but implementation risk is high

Balance Sheet Risk: MODERATE

  • Debt increased 27% in 2025 ($3.12B to $3.95B)
  • Operating cash flow was negative in 2025
  • If 2026 FCF is also negative, debt servicing becomes a concern
  • However, $4.25B cash cushion provides buffer

Medicare Exit Risk: LOW-MODERATE

  • Exiting traditional MAPD in 2027 reduces diversification
  • $1.00/share drag in 2026 from underperforming MAPD business
  • Long-term positive (removes money-losing segment)

7. Valuation

Current Metrics

Metric Value vs. 5yr Average
P/E (TTM) 16.7x Below avg (~18-20x)
P/E (2026E adj) 29.8x ($5.00 adj EPS) Elevated due to trough
Forward P/E (normalized) ~8-10x ($15-19 EPS) Very cheap if margins recover
P/B 1.87x Below avg (~3-4x)
EV/EBITDA 3.5x Very low
EV/Revenue 0.07x Extremely low
FCF Yield (5yr avg) 11.0% Attractive (using normalized FCF)

Intrinsic Value Estimation

Scenario 1: Margin Recovery (Base Case, 60% probability)

  • 2027-2028 EPS normalizes to $18-22 (pre-2025 levels)
  • Apply 14-16x P/E (historical mid-range for managed care)
  • Fair Value: $252-$352
  • Upside: 69-136% from current

Scenario 2: Partial Recovery (Bear Case, 30% probability)

  • Margins recover to ~3.0% (below historical 3.7-4.6%)
  • 2027-2028 EPS: $12-15
  • Apply 12-14x P/E (discounted for lower quality)
  • Fair Value: $144-$210
  • Upside: -3% to +41%

Scenario 3: Structural Impairment (Worst Case, 10% probability)

  • Medicaid underfunding persists, government cuts Medicaid spending
  • 2027-2028 EPS: $5-8
  • Apply 10-12x P/E
  • Fair Value: $50-$96
  • Downside: 36-67%

Probability-Weighted Fair Value: ~$210-$260

Entry Prices

Level Price Implied P/E (Normalized) Margin of Safety
Strong Buy $110 ~6x normalized EPS 50-58% to fair value
Accumulate $135 ~7.5x normalized EPS 36-48% to fair value
Current $149 ~8.3x normalized EPS 29-43% to fair value

The stock briefly touched $121.06 in February 2026 -- that was near strong buy territory.

8. Why Burry and Klarman Are Buying

Michael Burry's Thesis (Scion Capital, ~35% of portfolio)

Burry compared Molina to "early GEICO" -- an insurer with superior operating efficiency trading at depressed prices during a cyclical trough. His key points:

  • Molina will "make money in Medicaid in 2026 while most competitors lose money"
  • Operational efficiency (low G&A) provides structural advantage during downturns
  • The stock is pricing in permanent impairment when the issue is temporary rate lag
  • Called it a "diamond in the rough"

Seth Klarman's Thesis (Baupost, 2.05% of portfolio)

Klarman initiated a $108M position (625,000 shares at ~$173 average cost) in Q4 2025:

  • Focus on "essential, recurring revenue streams"
  • Defensive healthcare positioning with "favorable regulatory dynamics and demographic tailwinds"
  • Alongside existing managed care holdings (Elevance Health)
  • Classic Klarman pattern: buying into forced selling and fear

What Their Convergence Signals

When two of the most disciplined value investors with very different styles (Burry = concentrated contrarian, Klarman = margin of safety absolutist) independently converge on the same stock at the same time, it strongly suggests:

  1. The selloff is creating genuine value, not a value trap
  2. The business is not structurally impaired
  3. The market is mispricing cyclical headwinds as permanent

9. Catalysts

Positive Catalysts

  1. Medicaid rate increases (2H 2026 - 2027): As states incorporate higher-cost data, rates should catch up to costs
  2. Florida contract ramp (2027+): Once implementation drag passes, $5B premium contract is highly accretive
  3. Georgia contract (~$2B annual premium): New market entry adds membership scale
  4. Medicare MAPD exit (2027): Removes money-losing segment, improves overall MCR
  5. Share buybacks at trough prices: If management buys back shares at $120-$150, it is extremely accretive vs. buying at $300+
  6. Industry consolidation: Molina is an attractive M&A target for larger MCOs

Negative Catalysts

  1. Federal Medicaid cuts: Block grant proposals or per-capita caps
  2. Delayed rate recovery: States slow to adjust rates due to budget constraints
  3. Another bad quarter: Q1 2026 miss could push stock to new lows
  4. ACA subsidy expiration: Marketplace membership could decline
  5. Balance sheet stress: Another year of negative FCF would be concerning

10. Investment Thesis

Molina Healthcare is a well-run, pure-play government managed care operator trading at its most attractive valuation in years following a cyclical margin trough driven by Medicaid rate underfunding. The business model -- administering essential healthcare coverage for 5.5 million low-income Americans -- provides recession-resistant revenue with a regulatory moat favoring incumbents.

The Q4 2025 disaster (GAAP loss, negative FCF, 94.6% MCR) is the culmination of a Medicaid rate lag cycle where utilization surged post-redetermination but rates have not yet caught up. Management estimates 300-400 bps of underfunding nationally, and actuarial rate corrections are mathematically inevitable -- states cannot indefinitely pay below-cost rates without losing MCO participation.

At $149, the stock trades at 1.87x book, 0.07x revenue, and roughly 8x normalized earnings -- deeply depressed for a company that generated 23% average ROE over the prior four years. Both Klarman and Burry have made significant bets on the recovery. The key risks are timing (how long until rates normalize), government policy (Medicaid funding is a political football), and balance sheet resilience (can Molina weather another year of negative FCF).

Recommendation: WAIT. Current price offers reasonable value, but the $121 low from February shows the stock can go lower if Q1 2026 disappoints. Accumulate at $125-135 for a 30-40% margin of safety to normalized fair value. Strong buy below $110 where the risk/reward becomes asymmetric.

This is not a "sleep well at night" stock -- it requires conviction that Medicaid rate cycles mean-revert and tolerance for 2-3 years of compressed earnings. But for patient investors willing to underwrite cyclical trough risk in an essential-service business backed by two of the world's best value investors, MOH offers compelling risk-adjusted returns.

Appendix: Key Financial Data

Quarterly EPS Trend (Last 8 Quarters)

Quarter Revenue GAAP EPS Adj EPS MCR
Q4 2025 $11.38B -$3.15 -$2.75 94.6%
Q3 2025 $11.48B $1.51 $1.84 92.6%
Q2 2025 $11.43B $4.75 $5.48 90.3%
Q1 2025 $11.15B $5.45 $6.08 89.7%
Q4 2024 $10.50B $4.44 $5.05 90.2%
Q3 2024 $10.34B $5.65 $6.01 89.2%
Q2 2024 $9.88B $5.17 $5.86 89.8%
Q1 2024 $9.93B $5.17 $5.73 89.0%

2026 Guidance Summary

Metric 2026 Guidance
Premium Revenue $42.2B (-2% vs 2025)
GAAP EPS >= $3.20
Adjusted EPS >= $5.00
Consolidated MCR 92.6%
Medicaid MCR 92.9%
Medicare MCR 94.0%
Marketplace MCR 85.5%
G&A Ratio (Adj) 6.4%

Share Count Reduction

Year Diluted Shares (M) Buybacks
2025 52.9M $1,037M
2024 56.5M $1,057M
2023 58.6M $60M
2022 57.8M $454M
2021 58.4M $181M

Data Sources: AlphaVantage API (financial statements, earnings), Molina Healthcare Q4 2025 earnings release (investors.molinahealthcare.com), StockAnalysis.com (financial data cross-reference), WebSearch (Klarman/Burry positions, management data).